Adaptive nanopore sequencing to determine pathogenicity of BRCA1 exonic duplication.
Mathilde FilserMathias SchwartzKevin MerchadouAbderaouf HamzaMarie-Charlotte VillyAntoine DeceesEléonore FrouinElodie GirardSandrine M CaputoVictor RenaultVéronique BecetteLisa GolmardNicolas ServantDominique Stoppat-LyonnetOlivier DelattreChrystelle ColasJulien Masliah-PlanchonPublished in: Journal of medical genetics (2023)
BRCA1 and BRCA2 are tumour suppressor genes that have been characterised as predisposition genes for the development of hereditary breast and ovarian cancers among other malignancies. The molecular diagnosis of this predisposition syndrome is based on the detection of inactivating variants of any type in those genes. But in the case of structural variants, functional consequences can be difficult to assess using standard molecular methods, as the precise resolution of their sequence is often impossible with short-read next generation sequencing techniques. It has been recently demonstrated that Oxford Nanopore long-read sequencing technology can accurately and rapidly provide genetic diagnoses of Mendelian diseases, including those linked to pathogenic structural variants. Here, we report the accurate resolution of a germline duplication event of exons 18-20 of BRCA1 using Nanopore sequencing with adaptive sampling target enrichment. This allowed us to classify this variant as pathogenic within a short timeframe of 10 days. This study provides a proof-of-concept that nanopore adaptive sampling is a highly efficient technique for the investigation of structural variants of tumour suppressor genes in a clinical context.